|
5th July 2004 De Novo and Peakdale complete GPCR library De Novo Pharmaceuticals, a Cambridge, UK-based computational drug design company, says that its collaboration with Peakdale Molecular has resulted in the successful launch of a new range of Peakexplorer screening compound libraries designed with the help of De Novo's computational drug design platform SkelGen. The first library is focused on G-Protein Coupled Receptors and contains over 1,000 well-characterized, highly diverse proprietary drug-like compounds. Peakexplorer G1 was created through a novel process that combines De Novo's modelling, computational design and virtual screening with Peakdale's proprietary chemistry and parallel synthesis capabilities. De Novo generated 15 million virtual structures, around 1,000 of which were synthesized by Peakdale in this first collection. Bart Wuurman, chief executive of De Novo, commented: "we are very pleased with the launch of Peakexplorer G1. In addition to licensing our technology to pharmaceutical companies like Roche and Lilly, this GPCR library further validates our computational approach to drug discovery."
|
